BRIEF-Aim Immunotech Reports Year-End Positive Phase 2 Interim Progress For Ampligen® (Rintatolimod) Plus Astrazeneca’S Imfinzi® (Durvalumab) In Pancreatic Cancer

AIM ImmunoTech Inc. Common Stock +8.18%

AIM ImmunoTech Inc. Common Stock

AIM

0.59

+8.18%

Feb 5 (Reuters) - AIM ImmunoTech Inc AIM.A:

  • AIM IMMUNOTECH REPORTS POSITIVE YEAR-END INTERIM CLINICAL PROGRESS FROM PHASE 2 STUDY EVALUATING AMPLIGEN® (RINTATOLIMOD) IN COMBINATION WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB) FOR THE TREATMENT OF PANCREATIC CANCER

Source text: ID:nGNX5VD198

Further company coverage: AIM.A


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.